Genetic Panel Predicts Breast Cancer Survival

Share this content:
Genetic Panel Predicts Breast Cancer Survival
Genetic Panel Predicts Breast Cancer Survival

(HealthDay News) — Changes in expression of a panel of 55 genes, linked with tumor suppressor gene SYK, in patients with breast cancer predicts both survival and whether or not the cancer will become invasive, according to a study published online Feb. 11 in PLOS ONE.

Jan Blancato, PhD, from Georgetown University in Washington, DC, and colleagues examined allelic loss of SYK in eight cases of breast ductal carcinoma in situ (DCIS), 11 cases of invasive ductal carcinoma adjacent to the DCIS, and five benign cases.

The researchers found that no allelic loss of SYK was detected in any of the DCIS-only or benign cases, compared with 46% of the DCIS with adjacent invasive ductal carcinoma. Based on changes in gene expression after knocking down expression of SYK, they identified 55 genes that interacted with SYK or were involved in motility and metastasis.

RELATED: Breast Cancer Resource Center

An analysis of breast cancer patients in The Cancer Genome Atlas showed that, after 18 years follow up, survival was about 80% for patients with no changes in expression of the 55 genes, compared with 20% survival for patients with changes.

"We conclude that reduction in SYK expression and contributions of genomic instability to copy number and mutations in the 55 SYK interacting genes significantly contribute to poorer overall patient survival," Blancato and colleagues wrote.


  1. Blancato J, Graves A, Rashidi B, et al. SYK Allelic Loss and the Role of Syk-Regulated Genes in Breast Cancer Survival. PLoS One. 2014;doi:10.1371/journal.pone.0087610.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs